---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-227875"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2026-05-18T11:15:07+00:00"
generated_at: "2026-05-18T11:21:25.255362+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics reports positive Phase 1/2 data for DT-216P2 in Friedreich ataxia

## Summary
- After 4 weeks at 1 mpk, mFARS improved 6.4 points, Upright Stability Score 2.7 points, fatigue >5 points (PROMIS).
- Whole blood FXN mRNA increased 65% (p<0.001); muscle FXN mRNA up 42% (p=0.015); FXN protein increased 22-27%.
- DT-216P2 well-tolerated; no serious adverse events or discontinuations; mild-moderate transient ALT elevations in 3 patients.
- Company plans to pursue registrational path; update expected in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-227875
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2026-05-18T11:15:07+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312526227875/0001193125-26-227875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312526227875/d154773d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-227875
- JSON: https://secwatch.observer/filing/0001193125-26-227875.json
- Plain text: https://secwatch.observer/filing/0001193125-26-227875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.